Ona Therapeutics — Series A · €30M

A €30M Series A with existing investor Asabys Partners and new investors Alta Life Sciences, Bpifrance (InnoBio 2), Fund+ and Ysios Capital. No lead was named, and each new investor took a board seat. The round financed development of the first-in-class antibody programmes against metastasis-initiating cells.

Lead not disclosed RoundSeries A Announced17 Jun 2020 CityBarcelona SectorHealthtech & Bio · Biotech Source O

Something wrong? Suggest a correction →